Aligos Therapeutics Inc (ALGS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $5.17 (+0.00%), Market cap $0.04B, 52-week low–high $5.25 ~ $13.29.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collabor
Financial statements, price targets, institutional (13F) holdings and related news for Aligos Therapeutics Inc are updated in real time on BlackAll Trade.
Aligos Therapeutics Inc trades at $5.17 (+0.00%). Real-time quotes and charts are available on BlackAll Trade.
Aligos Therapeutics Inc has a market cap of about $0.04B.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate,